BLESSING Diagonal-Needle RF & Injection
Korean platform combining diagonal-needle RF, direct injection, and subcision-like action
About This Treatment
BLESSING is a microneedle RF platform developed by South Korean manufacturer Cellah Medical. It includes DRS with diagonally entering needles, VRS with vertical needles, and ORS with a single-pin electrode. The manufacturer describes DRS as combining RF delivery, injectable placement, and a subcision-like scar-release effect.
The system received U.S. FDA 510(k) clearance in May 2025, but only for electrocoagulation and hemostasis in dermatologic and general surgical procedures. The clearance does not establish efficacy for cosmetic rejuvenation, acne-scar subcision, or drug delivery. No BLESSING-specific peer-reviewed human clinical study was identified as of August 17, 2026; counseling must distinguish indirect RF-microneedling and conventional-subcision evidence from manufacturer claims.
Mechanism of Action
FDA K243176 describes bipolar or monopolar RF at 1 or 2 MHz, with tissue resistance producing heat and focal coagulation. The 0.28-mm D-N10 DRS tip is designed to enter the skin diagonally. Cellah says this track mechanically crosses shallow fibrotic tethering while a lumen delivers an injectate together with RF, but incremental drug-delivery and scar-release benefits have not been validated in product-specific peer-reviewed human trials and are not part of the FDA-cleared indication.
Indications
Expected Results
No BLESSING-specific response rate or durability has been established in peer-reviewed human studies. A 2025 systematic review of 16 fractional RF-microneedling studies and 481 patients found the device class likely effective for acne scars, but studies were heterogeneous and further randomized trials are needed. Expected changes should therefore be described as class-inferred, gradual improvement in scars, texture, pores, and firmness over several weeks to 1-3 months after a series. Incremental benefit over devices such as Potenza, conventional subcision, or injection alone is unknown.
Clinical Evidence
Risks & Side Effects
Erythema, edema, warmth, pain, pinpoint bleeding, bruising, crusting, pigment change, burns, blistering, infection, herpes reactivation, scarring, fat loss, contour change, numbness, and nerve injury may occur. Diagonal-needle or subcision-like manipulation adds potential vessel, nerve, and deeper-tissue injury. Injectates add product-specific risks including allergy, delayed inflammation, nodules or granuloma, infection, intravascular injection or occlusion, and necrosis; sterility, local authorization, injection plane, and emergency readiness must be confirmed.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition